TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kessler Topaz Meltzer & Check, Llp
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations by uniQure N.V. after the FDA rejected sufficient evidence for the company's AMT-130 gene therapy BLA submission on November 3, 2025. The announcement caused uniQure's stock to plummet over 50%, falling from $67.69 to $34.29. The firm is encouraging affected investors to contact them regarding the potential class action lawsuit.

Insights
JPM   neutral

Participating as lead bank in a standard syndicated loan arrangement without exceptional risks or opportunities


QURE   negative

FDA rejected sufficient evidence for AMT-130 BLA submission, causing stock to fall over 50% in a single day. The company faces regulatory setback, unclear timeline for product approval, and potential securities litigation.